These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 9408021)

  • 1. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
    Chino D; Fujita Y; Ishii K; Nakayama K
    J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
    Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
    Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
    Kaiser B; Jeske W; Walenga JM; Fareed J
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
    Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
    J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
    Ieko M; Tarumi T; Takeda M; Naito S; Nakabayashi T; Koike T
    J Thromb Haemost; 2004 Apr; 2(4):612-8. PubMed ID: 15102016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
    Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
    Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
    Hayashi M; Matsuo A; Nakamoto H; Aisaka K
    Eur J Pharmacol; 2001 Jan; 412(1):61-6. PubMed ID: 11166737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
    Nagashima H
    J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.